glp-1 and breast cancer risk GLP-1s in Oncology: Nursing Insights Survivorship GLP-1 Agonists Poised to Impact

Oral Wegovy (Semaglutide Pill) For those preferring an oral alternative, Oral Wegovy offers the same semaglutide formula in a daily tablet

AMPLITUDE-O with efpeglenatide, the latest GLP-1 RA CVOT to report (Gerstein et al., 2021), indeed indicated a benefit on HF, with post hoc analyses showing a significant 39% relative risk reduction on HF requiring hospitalisation (HR 0.61

DeFronzo RA, Buse JB, Kim T, Burns C, Skare S, Baron A, Fineman M

Individuals who choose to use GLP-1 medications can often protect their hair by addressing key internal factors, including: adequate protein intake balanced micronutrient levels metabolic stability reduced inflammatory stress Hair follicles are highly responsive to the bodys internal environment

A Statistically Significant Risk

Contact your GP for routine assessment if: Urinary frequency significantly disrupts daily activities or sleep You notice persistent changes in urine colour, smell, or appearance Urinary symptoms persist beyond the initial adjustment period (typically 48 weeks) You have concerns about medication side effects or diabetes control Your healthcare provider can perform appropriate investigations, including urinalysis, renal function tests, and HbA1c measurement, to determine the underlying cause of urinary changes and adjust your treatment plan accordingly